title: Proteomic analysis of early response lymph node proteins in mice treated with titanium dioxide nanoparticles.
abstract: Human exposure to nanoparticles is inevitable from natural and anthropogenic sources. Titanium dioxide (TiO2) nanoparticles are increasingly being used in pharmaceutical and cosmetic products. Previous studies revealed that TiO2 levels were significantly increased in tissues (e.g., lymph nodes) after mice were injected with nanosized TiO2. To identify early response lymph node proteins to TiO2 nanoparticles, groups of mice were intradermally injected with a low dose of DeGussa P25 TiO2 nanoparticles or vehicle alone. The proteomes of lymph nodes at 24 h were quantitatively analyzed using trypsin-catalyzed 16O/18O labeling in conjunction with two-dimensional liquid chromatography separation and tandem mass spectrometry (2DLC-MS/MS). A total of 33 proteins were significantly changed (over 1.3-fold, p<0.05) in the mice treated with TiO2 nanoparticles, which accounted for approximately 1% of the total proteins identified. The differentially expressed proteins mainly involve the immune response (e.g., inflammation), lipid and fatty acid metabolism, mRNA processing, and nucleosome assembly. Regulation of functionally distinct classes of proteins could be mediated by estrogen receptor (ESR1), PPARγ, and c-Myc signalings, etc. The differentially expressed proteins identified in this experiment could represent early response proteins to TiO2 nanoparticle treatment in mouse lymph nodes.
authors: Center of Excellence for Proteomics, Division of Systems Biology, National Center for Toxicological Research, FDA, Jefferson, AR 72079, USA.
authors: Yuan
authors: Y
authors: Gao
authors: Neera V
authors: NV
authors: Gopee
authors: Paul C
authors: PC
authors: Howard
authors: Li-Rong
authors: LR
authors: Yu
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D008198:Lymph Nodes / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage*; D020543:Proteome / Q000276:immunology / Q000378:metabolism*; D040901:Proteomics / Q000379:methods*; D014025:Titanium / Q000008:administration & dosage*
chemical_list: D001672:Biocompatible Materials; D020543:Proteome; C009495:titanium dioxide; D014025:Titanium